GRAIL, Inc.
Close on Oct 19, 2026
- Market cap
- $5.28B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $44.70M | $-2.56 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $40.80M | $-2.29 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 19, 2026 | After market close | $43.60M | $-2.44 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $36.20M | $-2.46 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | $35.50M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $31.80M | $-3.10 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 20, 2025 | After market close | $38.30M | $-2.89 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $28.70M | $-3.94 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Jan 12, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Cash burn | 2026 | $300.00M | New |
| Total Galleri revenue | 2026 | 22% to 32% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Grail filed with the SEC
GRAIL Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
GRAIL Analyst Call American Society of Clinical Oncology May 31, 2026 1
Executive or director change · Other events · EX-99.1 to Form 8-K
GRAIL Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
Results of operations · Other events · EX-99.2 to Form 8-K
44th Annual J.P. Morgan Healthcare Conference January 12, 2026 1 Bob Ragusa, Chief Executive Officer Josh Ofman, President
Results of operations · EX-99.1 to Form 8-K
GRAIL Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL’s Galleri ® Multi-Cancer Early Detection Test to Asia
Material agreement · Results of operations · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
GRAIL Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
GRAIL Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
43rd Annual J.P. Morgan Healthcare Conference Bob Ragusa, CEO January 2025 CONFIDENTIAL & PROPRIETARY 1
Results of operations · EX-99.1 to Form 8-K
GRAIL Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
GRAIL Appoints Sarah Krevans to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update
Results of operations · EX-99.1 to Form 8-K
We are sending you this Information Statement in connection with Illumina, Inc.s partial spin-off
Other events · EX-99.1 to Form 8-K